Cardiorenal syndrome: pathophysiological mechanism, preclinical models, novel contributors and potential therapies
Authors:
- Fu QiangFQFu Qiang
- Cao LongxingCLCao Longxing
- Li HuangLHLi Huang
- Wang BinghuiWBWang Binghui
- Li ZhiliangLZLi Zhiliang
- 20 August 2014
- journal article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 127 (16) , 3011-3018
Abstract
Ish up to January 2014. Study selection Original articles and critical reviews related to cardiorenal syndrome were selected and carefully analyzed. Results Cardiorenal syndrome is a condition characterized by kidney and heart failure where failure of one organ worsens the function of the other thus further accelerating the progressive failure of both organs. The pathophysiology of cardiorenal syndrome is not fully understood, but may be caused by a complex combination of neurohormonal system activation, endothelial dysfunction, proteinuria, oxidative stress, uremic toxins and other factors. Managing cardiorenal syndrome is still a major therapeutic challenge in clinical practice because many of the drugs used to control heart failure can worsen renal function, and vice versa. Non-dialyzable uremic toxins, such as indoxyl sulfate, causing detrimental effects on the heart and kidney as well as stimulation of inflammatory responses, may be an effective therapeutic target for cardiorenal syndrome. Conclusions Suitable disease models of cardiorenal syndrome are urgently needed to investigate the pathophysiology and effective therapeutic approaches to the condition. Non-dialyzable protein-bound uremic toxins that may have cardiac and renal effects may provide therapeutic benefit to cardiorenal syndrome patients....Keywords
This publication has 79 references indexed in Scilit:
- Chronic Kidney Disease-Induced Cardiac Fibrosis Is Ameliorated by Reducing Circulating Levels of a Non-Dialysable Uremic Toxin, Indoxyl SulfatePLOS ONE, 2012
- Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: implications for cardiorenal syndromeAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Role of homocysteine in aortic calcification and osteogenic cell differentiationAtherosclerosis, 2009
- AST-120 Treatment in Pre-Dialysis Period Affects the Prognosis in Patients on HemodialysisRenal Failure, 2008
- Relation of Loop Diuretic Dose to Mortality in Advanced Heart FailureThe American Journal of Cardiology, 2006
- Kidney Disease as a Risk Factor for Development of Cardiovascular DiseaseHypertension, 2003
- Involvement of Nuclear Factor-κB and Apoptosis Signal-Regulating Kinase 1 in G-Protein–Coupled Receptor Agonist–Induced Cardiomyocyte HypertrophyCirculation, 2002
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- ERK2 Activation by Homocysteine in Vascular Smooth Muscle CellsBiochemical and Biophysical Research Communications, 1998